keyword
https://read.qxmd.com/read/36828465/the-relationship-between-pain-and-spasticity-and-tell-tale-signs-of-pain-in-children-with-cerebral-palsy
#1
JOURNAL ARTICLE
Christian Wong
Pain and quality of life are closely interrelated in children with cerebral palsy (CCP). Even though 67% of CCP experience pain, it is overlooked and untreated. In this study, our purpose was two-fold: first, to examine the relationship between pain and spasticity by evaluating the effects of AbobotulinumtoxinA/Dysport (BoNT), and second, to describe the symptoms and location of pain in CCP. The subjects were 22 CCP in at least moderate pain. They were evaluated for spasticity by the modified Ashworth and Tardieu scale and for pain by the r-FLACC and the pediatric pain profile...
February 13, 2023: Toxins
https://read.qxmd.com/read/36119669/experiences-of-patients-with-poststroke-spasticity-throughout-a-botulinum-toxin-treatment-cycle-results-from-a-prospective-ethnographic-study
#2
JOURNAL ARTICLE
Jorge Jacinto, Andreas Lysandropoulos, Marjorie Leclerc, Françoise Calvi-Gries
This study was conducted to capture the experience of patients with poststroke spasticity (PSS) throughout one botulinum neurotoxin A (BoNT-A) treatment cycle. The REBOT study (NCT03995524) was a prospective, observational ethnographic study conducted in France, Italy, the UK, and the USA. It combined a mixed-method ethnography (including semi-structured qualitative interviews within a week of a BoNT-A injection) with completion of a longitudinal quantitative patient-reported outcome questionnaire and sharing of video and images, both reported weekly over a 12-14-week period throughout the BoNT-A treatment cycle...
2022: Frontiers in Neurology
https://read.qxmd.com/read/35730362/the-cost-effectiveness-of-abobotulinumtoxina-dysport-and-onabotulinumtoxina-botox-for-managing-spasticity-of-the-upper-and-lower-limbs-and-cervical-dystonia
#3
JOURNAL ARTICLE
Natalya Danchenko, Karissa M Johnston, John Whalen
OBJECTIVE: To evaluate the costs and benefits associated with the use of abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) for lower limb spasticity in children, upper and lower limb spasticity in adults, and cervical dystonia in adults. METHODS: This pharmacoeconomic analysis compared aboBoNT-A with onaBoNT-A. A decision tree model with a 1-year time horizon was conducted from a UK National Health Service (NHS) perspective using data from a variety of sources: randomized controlled trials (RCTs), network meta-analyses (NMAs), observational studies, and a physician survey investigating treatment patterns and resource utilization...
January 2022: Journal of Medical Economics
https://read.qxmd.com/read/34932284/-impact-of-integrated-upper-limb-spasticity-management-including-repeat-botulinum-toxin-type-a-bont-a-injections-on-patient-centred-goal-attainment-in-real-life-practice-results-from-the-prospective-observational-upper-limb-international-spasticity-cohort-study
#4
MULTICENTER STUDY
S E Khat'kova, A Baikova, P Maisonobe, D R Khasanova
OBJECTIVE: To assess the longitudinal attainment of patient-centred and function related goals after integrated spasticity management including repeated cycles of botulinum toxin A type A (BoNT-A) injections in real life settings over a period of 2 years. The article presents analysis of the results within the subpopulation of patients from Russia. MATERIAL AND METHODS: This international, multicentre, observational, prospective, longitudinal cohort study (registered at clinicaltrials...
2021: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://read.qxmd.com/read/34852255/cost-efficiency-analysis-for-spasticity-management-based-on-physician-botulinum-toxin-prescribing-habits
#5
JOURNAL ARTICLE
Rashid Kazerooni, Ileana Howard, Xiaomeng Li, Monica Verduzco-Gutierrez
OBJECTIVE: To estimate differences in botulinum toxin type A (BoNT-A) treatment costs per patient for spasticity-injecting physicians, with a focus on physicians' use of alternative BoNT-A agents other than onabotulinumtoxinA. DESIGN: Retrospective cohort study. SETTING: National Medicare data for fee-for-service beneficiaries in 2017. PARTICIPANTS: A total of 116 physicians, 6829 BoNT-A procedures, and 3051 patients were included in this analysis...
June 2022: Archives of Physical Medicine and Rehabilitation
https://read.qxmd.com/read/34803878/muscle-selection-and-dosing-in-a-phase-3-pivotal-study-of-abobotulinumtoxina-injection-in-upper-limb-muscles-in-children-with-cerebral-palsy
#6
JOURNAL ARTICLE
Joyce Oleszek, Ann Tilton, Jorge Carranza Del Rio, Nigar Dursun, Marcin Bonikowski, Edward Dabrowski, Simon Page, Benjamin Regnault, Catherine Thompson, Mauricio R Delgado
Background: Guidelines recommend botulinum toxin-A in pediatric upper limb spasticity as part of routine practice. Appropriate dosing is a prerequisite for treatment success and it is important that injectors have an understanding on how to tailor dosing within a safe and effective range. We report upper limb dosing data from a phase 3 study of abobotulinumtoxinA injections in children with cerebral palsy. Methods: This was a double-blind, repeat-treatment study (NCT02106351). In Cycle 1, children were randomized to abobotulinumtoxinA at 2 U/kg control dose or clinically relevant 8 U/kg or 16 U/kg doses...
2021: Frontiers in Neurology
https://read.qxmd.com/read/34207357/efficacy-and-optimal-dose-of-botulinum-toxin-a-in-post-stroke-lower-extremity-spasticity-a-systematic-review-and-meta-analysis
#7
JOURNAL ARTICLE
Thanh-Nhan Doan, Mei-Ying Kuo, Li-Wei Chou
Post-stroke spasticity impedes patients' rehabilitation progress. Contradictory evidence has been reported in using Botulinum Neurotoxin type A (BoNT-A) to manage post-stroke lower extremity spasticity (PLES); furthermore, an optimum dose of BoNT-A for PLES has not yet been established. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to identify the efficacy and optimal dose of BoNT-A on PLES. "Meta" and "Metafor" packages in R were used to analyze the data...
June 18, 2021: Toxins
https://read.qxmd.com/read/33206382/efficacy-and-safety-of-abobotulinumtoxina-for-upper-limb-spasticity-in-children-with-cerebral-palsy-a-randomized-repeat-treatment-study
#8
RANDOMIZED CONTROLLED TRIAL
Mauricio R Delgado, Ann Tilton, Jorge Carranza-Del Río, Nigar Dursun, Marcin Bonikowski, Resa Aydin, Iwona Maciag-Tymecka, Joyce Oleszek, Edward Dabrowski, Anne-Sophie Grandoulier, Philippe Picaut
AIM: To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing upper limb spasticity in children with cerebral palsy (CP). METHOD: This was a double-blind, repeat-cycle study (NCT02106351) in children with CP (2-17y). Children were randomized to receive 2U/kg (control), 8U/kg, or 16U/kg abobotulinumtoxinA injections into the target muscle group (wrist or elbow flexors) and additional muscles alongside occupational therapy via a home-exercise therapy program (HETP; minimum five 15min sessions/wk)...
May 2021: Developmental Medicine and Child Neurology
https://read.qxmd.com/read/33101184/duration-of-symptom-relief-between-injections-for-abobotulinumtoxina-dysport%C3%A2-in-spastic-paresis-and-cervical-dystonia-comparison-of-evidence-from-clinical-studies
#9
JOURNAL ARTICLE
Alberto Esquenazi, Mauricio R Delgado, Robert A Hauser, Philippe Picaut, Keith Foster, Andreas Lysandropoulos, Jean-Michel Gracies
Background: Botulinum toxin-A is a well-established treatment for adult and pediatric spastic paresis and cervical dystonia. While guidelines and approved labels indicate that treatment should not occur more frequently than every 12 weeks, studies and real-world evidence show that the timing of symptom recurrence between treatments may vary. Methods: We report retreatment criteria and response duration (retreatment intervals) from four pivotal, double-blind, placebo-controlled studies with open-label extensions involving patients treated with abobotulinumtoxinA (aboBoNTA) for upper limb (NCT01313299) or lower limb (NCT01249404) spastic paresis in adults, lower limb spastic paresis in children (NCT01249417), and cervical dystonia in adults (NCT00257660)...
2020: Frontiers in Neurology
https://read.qxmd.com/read/32741133/the-effect-of-repeated-abobotulinumtoxina-dysport%C3%A2-injections-on-walking-velocity-in-persons-with-spastic-hemiparesis-caused-by-stroke-or-traumatic-brain-injury
#10
RANDOMIZED CONTROLLED TRIAL
Alberto Esquenazi, Allison Brashear, Thierry Deltombe, Monika Rudzinska-Bar, Malgorzata Krawczyk, Alexander Skoromets, Michael W O'Dell, Anne-Sophie Grandoulier, Claire Vilain, Philippe Picaut, Jean-Michel Gracies
BACKGROUND: Botulinum toxin (BoNT) injections were shown to improve muscle tone of limbs in patients with spasticity. However, limited data are available regarding the effects of repeated BoNT injections on walking ability. OBJECTIVE: To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT-A; Dysport) in spastic lower limb muscles. DESIGN: Secondary analysis of an open-label, multiple-cycle extension (National Clinical Trials number NCT01251367) to a phase III, double-blind, randomized, placebo-controlled, single-treatment cycle study, in adults with chronic hemiparesis (NCT01249404)...
May 2021: PM & R: the Journal of Injury, Function, and Rehabilitation
https://read.qxmd.com/read/32523646/efficacy-of-botulinum-toxin-a-for-the-treatment-of-hemiparesis-in-adults-with-chronic-upper-limb-spasticity
#11
JOURNAL ARTICLE
Sameh Ghroubi, Samar Alila, Wafa Elleuch, Houda Ben Ayed, Chokri Mhiri, Mohamed Habib Elleuch
Introduction: this study aimed to evaluate the effectiveness of botulinum toxin A (BoNT-A) injection in hemiparetic patients with chronic spasticity in the upper limb resulting from stroke or traumatic brain injury. Methods: we conducted a retrospective study including 45 patients seen, in our department of Physical Medicine and Rehabilitation, between January 2014 and December 2016. All patients received an injection of BoNT-A (Dysport, 100 U/ml). Affected upper-extremity muscles could be injected as per the investigator's discretion to a maximum total dose of 1000 U...
2020: Pan African Medical Journal
https://read.qxmd.com/read/32451555/abobotulinumtoxina-injections-in-shoulder-muscles-for-adult-upper-limb-spasticity-results-from-a-phase-4-real-world-study-and-a-phase-3-open-label-trial
#12
JOURNAL ARTICLE
Thierry Lejeune, Svetlana Khatkova, Lynne Turner-Stokes, Philippe Picaut, Pascal Maisonobe, Jovita Balcaitiene, François Constant Boyer
OBJECTIVE: To compare patients with upper limb spasticity who did or did not receive abobotulinumtoxinA (Dysport®) in shoulder muscles during 2 international clinical studies. DESIGN: Phase 4 Upper Limb International Spasticity Study-II (ULIS-II; NCT01020500) endpoints: primary goal selection and achievement. Phase 3 Adult Upper Limb open-label study (NCT01313299) endpoints: Disability Assessment Scale principal target of treatment and mean (standard deviation) change from baseline to week 4 (last cycle involving shoulder muscles) for pain, Modified Frenchay Scale (active function), and Tardieu Scale parameters...
May 25, 2020: Journal of Rehabilitation Medicine
https://read.qxmd.com/read/32318680/sore-throat-as-a-side-effect-of-abobotulinum-toxin-a-injection-for-upper-limb-spasticity-after-stroke-a-case-report
#13
Esra Giray, Evrim Karadag-Saygı
Despite sore throat exists in the product characteristics of abobotulinum toxin A as one of the side effects, no available reports of sore throat after abobotulinum toxin A injection for adult upper limb spasticity could be found in the literature to guide physicians for the management. Herein, we report a case of poststroke spasticity who develop sore throat immediately after abobotulinum toxin A (Dysport®) injection of forearm muscles which completely resolved after observation for eight hours. This case report highlights a rare side effect of abobotulinum toxin A and provides information regarding the follow-up process of side effects which would guide physicians for the management...
March 2020: Turkish journal of physical medicine and rehabilitation
https://read.qxmd.com/read/32305277/botulinum-toxin-type-a-for-upper-limb-spasticity-in-poststroke-patients-a-meta-analysis-of-randomized-controlled-trials
#14
REVIEW
Shiyu Jia, Yang Liu, Liuyan Shen, Xue Liang, Xiaomin Xu, Youdong Wei
BACKGROUND AND AIM: Botulinum toxin type A is considered to be an effective antispasmodic in recent years. We assess the effectiveness of botulinum toxin type A for the treatment of poststroke spasticity in the upper extremity using a meta-analysis. METHODS: We searched several databases including PubMed, Web of Science, Embase, and Cochrane database for relevant studies, up until October 2017. All randomized controlled trials of botulinum toxin type A treat poststroke upper limb spasticity published were included...
June 2020: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://read.qxmd.com/read/31956971/real-world-effectiveness-of-abobotulinumtoxina-dysport%C3%A2-in-adults-with-upper-limb-spasticity-in-routine-clinical-practice-an-observational-study
#15
JOURNAL ARTICLE
Iwona Sarzyńska-Długosz, Anna Szczepańska-Szerej, Artur Drużdż, Tomasz Łukomski, Stanisław Ochudło, Andrzej Fabian, Piotr Sobolewski, Katarzyna Mariańska, Joanna Maciejewska, Ewa Mulek, Alina Niedzielska, Romain Raymond, Magdalena M Brzózka, Maria Jessa-Jabłońska
AbobotulinumtoxinA (aboBoNT-A, Dysport®) is used in clinical practice as a well-tolerated and effective therapy for muscle spasticity. AboBoNT-A has been shown to reduce upper and lower limb spastic paresis in clinical trials, demonstrating improvements in muscle tone and limb function. This open-label, multicentre, observational, non-interventional study was the first to investigate aboBoNT-A's efficacy in adult patients with upper limb spasticity (ULS) in routine clinical practice in Poland. All enrolled patients received ≥1 aboBoNT-A injection cycles, per routine clinical practice (full analysis set, FAS), and ≥1 rehabilitation session...
January 20, 2020: Neurologia i Neurochirurgia Polska
https://read.qxmd.com/read/31820010/abobotulinumtoxina-and-rehabilitation-vs-rehabilitation-alone-in-post-stroke-spasticity-a-cost-utility-analysis
#16
JOURNAL ARTICLE
Carlo Lazzaro, Alessio Baricich, Alessandro Picelli, Patrizia Maria Caglioni, Marco Ratti, Andrea Santamato
OBJECTIVE: To investigate costs and quality-adjusted life years of rehabilitation combined with abobotulinumtoxinA (aboBoNT-A) (rehab/aboBoNT-A) vs rehabilitation alone (rehab) in post-stroke spasticity in Italy. DESIGN: Based on both Italian National Health Service and societal perspectives, a 2-year cost-utility analysis model was performed. Subject/patients: The cost-utility analysis model considered hypothetical patients. METHODS: The cost-utility analysis model was populated with data concerning demographics, disease severity, healthcare and non-healthcare resource consumption...
February 7, 2020: Journal of Rehabilitation Medicine
https://read.qxmd.com/read/31691605/efficacy-of-repeat-abobotulinumtoxina-dysport%C3%A2-injections-in-improving-gait-in-children-with-spastic-cerebral-palsy
#17
RANDOMIZED CONTROLLED TRIAL
Nigar Dursun, Marcin Bonikowski, Edward Dabrowski, Dennis Matthews, Mark Gormley, Ann Tilton, Jorge Carranza, Anne-Sophie Grandoulier, Philippe Picaut, Mauricio R Delgado
Purpose : This secondary analysis of a randomized, double-blind study plus open-label extension (NCT01249417/NCT01251380) evaluated the efficacy of abobotulinumtoxinA versus placebo in improving gait pattern in children with dynamic equinus due to cerebral palsy (CP) as assessed by the observational gait scale (OGS). Methods : Ambulatory children with CP (N = 241, aged 2-17) and dynamic equinus were randomized to treatment with abobotulinumtoxinA (10 or 15U/kg/leg) or placebo injected into the gastrocsoleus...
August 2020: Developmental Neurorehabilitation
https://read.qxmd.com/read/31529136/effects-on-walking-of-simultaneous-upper-lower-limb-abobotulinumtoxina-injections-in-patients-with-stroke-or-brain-injury-with-spastic-hemiparesis
#18
JOURNAL ARTICLE
Peter J McAllister, Svetlana E Khatkova, Steven G Faux, Philippe Picaut, Romain Raymond, Jean-Michel Gracies
OBJECTIVE: To compare walking speed in patients with spastic hemiparesis who received abobotulinumtoxinA either in the lower limb or simultaneously in both the lower and upper limbs. DESIGN: Post hoc analysis from a phase 3 study of abobotulinumtoxinA (Dysport®, NCT01251367). PATIENTS: Adult patients with spastic hemiparesis causing gait dysfunction. METHODS: Comfortable barefoot walking speed over 10 m was evaluated in patients receiving lower limb vs lower and upper limb injections over ≤4 treatment cycles; 1,000 U or 1,500 U in lower limb for cycle 1/2; optional upper limb injections from cycle 3 (500 U: upper limb, 1,000 U: lower limb)...
October 29, 2019: Journal of Rehabilitation Medicine
https://read.qxmd.com/read/30551641/abobotulinumtoxina-dysport-%C3%A2-onabotulinumtoxina-botox-%C3%A2-and-incobotulinumtoxina-xeomin-%C3%A2-neurotoxin-content-and-potential-implications-for-duration-of-response-in-patients
#19
COMPARATIVE STUDY
Malgorzata Field, Andrew Splevins, Philippe Picaut, Marcel van der Schans, Jan Langenberg, Daan Noort, Daniel Snyder, Keith Foster
Botulinum neurotoxin type-A (BoNT-A) blocks the release of acetylcholine from peripheral cholinergic nerve terminals and is an important option for the treatment of disorders characterised by excessive cholinergic neuronal activity. Several BoNT-A products are currently marketed, each with unique manufacturing processes, excipients, formulation, and non-interchangeable potency units. Nevertheless, the effects of all the products are mediated by the 150 kDa BoNT-A neurotoxin. We assessed the quantity and light chain (LC) activity of BoNT-A in three commercial BoNT-A products (Dysport® ; Botox® ; Xeomin® )...
December 13, 2018: Toxins
https://read.qxmd.com/read/30335069/-botulinum-toxin-in-treatment-of-lower-limb-spasticity-in-patients-with-brain-damage
#20
JOURNAL ARTICLE
A P Kovalenko, V K Misikov
AIM: To develop and test a method of examination of patients with lower limb spasticity, to describe lower limb spasticity patterns in patients with brain damage and to assess the efficacy of abobotulinumtoxin A (dysport) in the rehabilitation of patients with stroke. MATERIAL AND METHODS: Spasticity rating scales (MAS and Tardieu), the Barthel index, the Rankin scale , the Rivermead Mobility Index, the Hauser Ambulation Index, a comfortable walking test were used...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
keyword
keyword
32388
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.